evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

228 questions · 231 findings · 20 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 32 · 13.9%GRADE not reported 4 · 1.7%Very low 46 · 19.9%Low 80 · 34.6%Moderate 53 · 22.9%High 16 · 6.9%

Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone

Death (all causes) · women with locally advanced cervical cancer

It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes overall survival Median compared with chemoradiotherapy alone (very low certainty).

1 finding from 1 review

Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone

Progression or event‐free survival Median · women with locally advanced cervical cancer

It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes progression or event‐free survival Median compared with chemoradiotherapy alone (very low certainty).

1 finding from 1 review

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

Death (all causes) · women with locally advanced cervical cancer

Hysterectomy (simple or radical) with radiotherapy showed no clear difference in overall survival Median compared with radiotherapy alone (low certainty).

1 finding from 1 review

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 4): targeted therapy agent… leads to lower overall survival compared with control intervention alone (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 4): targeted therapy agent… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Toxicity · palliative participants with esophageal and GE‐junction carcinoma

It is very uncertain whether summary of findings table (subcomparison 4): targeted therapy agent… changes toxicity compared with control intervention alone (very low certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Mortality Median · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Progression/relapse · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Treatment‐related mortality · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review